Corgenix Expands Contract Services Business Unit
News May 03, 2013
Corgenix Medical Corporation announced the expansion of its Contract Services business and the launch of its dedicated Contract Services website, www.corgenix.net. The new site complements the existing www.corgenix.com site and reflects the company’s strong growth and dedicated strategic approach to its Contract Services business unit for diagnostic products.
“Contract Services, including contract manufacturing, contract development, companion diagnostics and partner support activities, has become an increasingly important part of our business, and as a result we are significantly expanding our capabilities,” said Corgenix President and Chief Executive Officer Douglass Simpson. “Our company is already an established industry leader for in vitro diagnostics development and manufacturing. As the demand for companion diagnostics grows, Corgenix is adding new resources to assist pharmaceutical and biotechnology companies with the development of these promising tests, which aid in stratifying patient populations and determining the effectiveness of specific corresponding therapies.”
The company’s Contract Services business is supported by a dedicated team of highly qualified and experienced scientific researchers, laboratory and operations professionals. Corgenix’ facilities function as a full-service operation to support and partner with its customers on everything from product concept to product distribution.
In addition to contract manufacturing services, the company’s portfolio of outsourced services includes:
• Product development
• Technology application
• Private labeling
• Regulatory management
• Warehousing and fulfillment
• Distribution and commercialization
For more than twenty years, Corgenix has provided Contract Services to large and small medical companies, pharmaceutical and biotechnology companies, universities, research institutions and government agencies. The company’s expertise, quality system, solid infrastructure and state-of-the-art manufacturing facility have attracted partners from across the globe.
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE